EditorialTherapeutic antibodies: Discovery, design and deployment
Section snippets
Conflicts of interest
P.A.R., none to declare; A.T.H. is a former employee of Immune System Therapeutics Ltd; P.J.C., none to declare.
Acknowledgements
The authors gratefully acknowledge the contribution toward this study from the Victorian Operational Infrastructure Support Program received by the Burnet Institute. A.T.H. is supported by a Chancellor's Postdoctoral Fellowship at the University of Technology Sydney as well as a Fulbright Scholarship from the Australian-American Fulbright Commission.
References (17)
- et al.
Clinical deployment of antibodies for treatment of melanoma
Mol. Immunol.
(2015) - et al.
Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies
Mol. Immunol.
(2015) - et al.
Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic
Mol. Immunol.
(2015) - et al.
In vivo imaging with antibodies and engineered fragments
Mol. Immunol.
(2015) - et al.
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
Mol. Immunol.
(2015) - et al.
Complement in therapy and disease: regulating the complement system with antibody-based therapeutics
Mol. Immunol.
(2015) - et al.
ImmTACs for targeted cancer therapy: why, what, how, and which
Mol. Immunol.
(2015) - et al.
Human antibody technology and the development of antibodies against cytomegalovirus
Mol. Immunol.
(2015)
Cited by (16)
ADME of Biologicals and New Therapeutic Modalities
2022, Comprehensive PharmacologyMammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing
2020, Biotechnology AdvancesCitation Excerpt :As well as the rise of biosimilars (McCamish and Woollett, 2012), next-generation biopharmaceutical therapeutics have gained extensive attention due to the obvious benefits in higher bioavailability, increased half-life, lower immunogenicity and will eventually create added value over existing products (Moorkens et al., 2017). As demonstrated in Fig. 2, next generation therapeutics covers a variety of products, including monoclonal antibodies, cellular and gene therapy products, protein and bioconjugates, peptides and oligonucleotides, vaccines and microbiome therapeutics (Hanna et al., 2017; Kim, 2013; Lundin et al., 2015; Mimee et al., 2016; Ramsland et al., 2015; Stephanopoulos and Francis, 2011; Vlahos and Coghlan, 2005). One promising emerging area is Chimeric Antigen Receptor (CAR) T-cell therapy, which is a form of immunotherapy involving genetic modification of patient’s autologous T-cells via viral-based or nonviral based gene transfer methods to target specific cancer/autoimmune cells.
A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential
2019, Antiviral ResearchCitation Excerpt :That year, six of the ten top selling drugs in the world were antibody drugs. As targeted therapies, antibodies have been widely used against human diseases, including cancer, autoimmunity and infectious diseases (Ramsland et al., 2015; Tan et al., 2013). However, the pathogenesis of most diseases may involve multiple antigen epitopes or virus subtypes or pathogens acting in several independent steps (Shi et al., 2016).
Polyclonal anti-Candida antibody improves phagocytosis and overall outcome in zebrafish model of disseminated candidiasis
2017, Developmental and Comparative ImmunologyCitation Excerpt :Nevertheless, the development of monoclonal antibodies for protection against candidemia has not yet realized its potential (Bromuro et al., 2002; Casadevall et al., 1998). Therapeutic antibodies can act through a number of different mechanisms to block microbial pathogenesis, including direct neutralization, enhancement of complement deposition and/or activation, augmentation of opsonic uptake, activation of natural killer cells, and blockade of adhesion (Ramsland et al., 2015). While many of these activities can be and have been evaluated in vitro with in the presence of host cells, these in vitro evaluations do not fully recapitulate the host environment (Golay and Introna, 2012).
Use of aptamers in immunoassays
2016, Molecular ImmunologyCitation Excerpt :Over the past decade several aptamers specific to immunoglobulins (Ig) of human, mouse and rabbit origin were obtained. Interest in this problem is quite understandable, as Ig-specific aptamers after immobilization could be applied not only to detect Igs but also to the industrial-scale isolation of therapeutic antibodies (Ramsland et al., 2015). A 23-long RNA aptamer, Apt8-2, with the ability to interact specifically and with high affinity with the Fc region of human IgG was prepared.
Pre-injection of Zebrafish (Danio rerio) tnfb Polyclonal Antibody Decreases the Mortality of Vibrio vulnificus Infected Zebrafish
2021, Frontiers in Veterinary Science